Ressenya de M. GLESSGEN (et al. ed.), 'Ex traditione innovatio. Miscellanea in honorem Max Pfister septuagenarii oblata'. Darmstadt: Wissenschaftliche Buchgesellschaft, 2002.

Certament ha de ser un motiu de satisfacció per a qualsevol mestre veure l"empremta deixada per l"obra pròpia juntament amb la que es reflecteix en la producció dels seus deixebles. En aquests volums editats en homenatge al professor Max Pfister amb motiu del seu setantè aniversari s"hi combinen encertadament aquestes dues facetes: els editors han estructurat aquest homenatge en dos volums. El primer recull escrits diversos del mateix Max Pfister de tema gal.loromànic o italoromànic; el segon articles de tema divers, però essencialment italoromànic, dels col.laboradors del LEI.

Lectotypification of Halymenia rodrigueziana J.Feldmann [= Sebdenia rodrigueziana (J.Feldmann) Codomier ex Athanasiadis (Sebdeniaceae, Rhodophyta)].

Here we designate as a lectotype of Halymenia rodrigueziana J. Feldmann the sheet JF2328 held in the Herbarium of J. Feldmann, included in the Herbarium of the Cryptogam Laboratory of the Muséum National d"Histoire Naturelle de Paris (PC). Also we present the correct citation of this species and for Sebdenia rodrigueziana (J. Feldmann) Codomier ex Athanasiadis.

L'aliança Polygonion avicularis Br.-Bl. ex Dich. 1933 als Pirineus Catalans

L'anàlisi de nombrosos inventaris procedents dels Pirineus centrals i orientals ens ha dut a realitzar una revisió de I'aliança Polygonion avicularis Br.-Bl. ex Dich 1933 en aquesta àrea. Reconeixem fins al moment sis associacions per a les quals donem la seva caracterització florística i ecologica, així com la seva distribució als Pirineus catalans. Descrivim, a més, una subass. scleranthetosum uncinatae del Rumici-Spergularietum rubrae, comunitat altimontana i subalpina pròpia dels sòls calcigats.

Omphalina Umbellifera (L. ex. Fr.)Quel. Novedad para la flora liquénica

Se da cuenta de la recolección en el Montseny, el Corredor y el Moixeró de varios basidiocarpos de Omphalina umbellifera(L. ex Fr. ) Quel. (= O. ericetorum (Pers.) M. Lange), en taludes y sobre madera en descomposición.

Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient

Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.

Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient

Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.

Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient

Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.

Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient

Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.

Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient

Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.

Variability of the radius growth at 25 years old Pinus uncinata Miller ex Mirbel in the North-East Spanish Pyrenees

It has been studied the variability of stem radial growth in four radius orientations at the age of 25 years old trees. The species was Pinus uncinata. The sampling sites, located in the North East Spanish Pyrenees belong to different plant communities. An ANOVA analysis was performed in order to find out which factors, the radio orientation, plant community of the site and tree itself are significative or have some kind of influence on the tree radial growth.

Effectiveness of substituting cyclosporin A with tacrolimus in reducing gingival overgrowth in renal transplant patients

Objectives: This study aims to evaluate the effectiveness of periodontal therapy combined with tacrolimus in the suppression of gingival overgrowth (GO) and the effect on GO of changing from cyclosporin A to tacrolimus. Patients and Methods: Sixteen renal transplant patients, averaging 52 years of age, whose kidney function was stable and were receiving treatment with cyclosporin A, were randomly assigned to one of two groups. In the experimental group, patients were instructed in oral hygiene and underwent periodontal treatment, whereas in the control group, only oral hygiene instructions were given. After the first visit and the change of medication from cyclosporine to tacrolimus in both groups, periodic clinical revisions were carried out for 3 months in order to assess the evolution of GO. Results: All patients showed a progressive decrease in GO. There were no statistically significant differences between the two groups (p>0.05). A greater decrease in GO occurred within the first month after changing the medication. Conclusions: No improved effectiveness in reducing GO was observed for periodontal therapy in combination with tacrolimus. Tacrolimus is an alternative to cyclosporine when attempting to avoid GO in patients with kidney transplants

Peucedanum schottii Besser ex DC., novedad para la Flora Iberica.

En otoño de 1984 tuvimos la ocasión de recolectar este orófito europeo, con fruto maduro, en la cumbre del macizo calcáreo de la 'Mare de Deu del Mont', próximo a la población de Besalú (Prepirineos orientales). Vive en los rellanos herbosos inclinados, fisuras y oquedades de la cumbre, muy localizado, en pastos mesoxerófilos del Festucion gautieri. Un inventario tomado en el lugar muestra la siguiente composición florística (exp. N, incl. 60°, cobert. 100%): Festuca gautieri 5.5, Peucedanum schottii 2.3, Veronica austriaca subsp. vahlii 1.1, Avenula mirandana 1.1, Cruciata glabra 1.1, Phyteuma orbiculare 1.1, Seseli montanum 1.1, Dianthus seguieri subsp. gautieri 1.1, Galium pinetorum + , Vicia sepium +, Campanula rotundifolia +, Moehringia muscosa +.1, Allium senescens +, Teucrium chamaedrys + , Asperula cynanchica +, Dactylis glomerata + , Dianthus monspeliacus +, Sedum reflexum +, Vincetoxicum hirundinaria subsp. intermedium +.

Quality of life in simultaneous pancreas-kidney transplant recipients

Currently, simultaneous pancreas-kidney transplantation (SPK Tx) is the treatment of choice in selected patients with type 1 diabetes mellitus (DM1) and terminal kidney failure (TRF). A functioning SPK transplant allows dialysis and insulin therapy to be discontinued and stabilizes or improves the complications of DM1. Nevertheless, to a greater or lesser degree, these complications (physical and psychological alterations, secondary effects of immunosuppressive therapy and the need for lifelong medication and medical follow-up) can persist after SPK Tx. Health professionals have mainly investigated the clinical features of transplant recipients. However, in the last few years, interest in analyzing perceived health and health-related quality of life (QoL) has increased. This latter concept includes the features of QoL most closely associated with a particular disease, its treatment and follow-up and therefore those elements most susceptible to modification by the health system. The general aim of this study was to measure health-related QoL in our population with SPK Tx and to determine whether there are significant differences between these patients and those with DM1 and TRF who continue to receive renal replacement therapy (RRT) and insulin therapy. More specific aims were to evaluate whether there are significant differences between the study groups and the means of the Spanish reference population in the distinct dimensions of a QoL questionnaire and whether other variables such as age, sex, years" duration of DM1, length of dialysis, and time since SPK Tx significantly affect health-related QoL.